10-Q: Tempest Therapeutics Reports Third Quarter 2024 Results, Advances Lead Cancer Program

Tempest Therapeutics reports its third quarter 2024 financial results and provides an update on its clinical programs, including the planned pivotal Phase 3 trial for amezalpat in liver cancer.

Summary

• Tempest Therapeutics is a clinical-stage biotechnology company focused on developing cancer treatments.
• The company's lead program, amezalpat, is preparing for a pivotal Phase 3 trial in first-line liver cancer, with positive feedback from the FDA on the trial design.
• Amezalpat showed a 6-month improvement in median overall survival (OS) compared to the control arm in a Phase 2 trial, reaching 21 months versus 15 months.
• The confirmed objective response rate (ORR) for amezalpat remained consistent at 30%, compared to 13.3% in the control arm.
• The company's second clinical program, TPST-1495, is being advanced into a Phase 2 study for Familial Adenomatous Polyposis (FAP).
• Tempest Therapeutics reported a net loss of $28.03 million for the nine months ended September 30, 2024, compared to a net loss of $22.003 million for the same period in 2023.
• As of September 30, 2024, the company had cash and cash equivalents of $22.1 million.
• The company has raised $19.9 million in net proceeds between October 1, 2024 and November 8, 2024 through sales of common stock under its ATM Program.
• The company believes its existing cash and cash equivalents will be sufficient to fund its cash requirements for at least 12 months following the issuance of these financial statements.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to the progress of the lead program, amezalpat, and the positive feedback from the FDA. However, the company's financial situation and need for additional funding temper the overall sentiment.

Positives

• Positive feedback from the FDA on the pivotal Phase 3 clinical trial design for amezalpat.
• Amezalpat demonstrated a significant improvement in overall survival in a Phase 2 trial.
• The company is expanding its clinical programs with TPST-1495 moving into a Phase 2 study.
• The leadership team has been strengthened with key appointments.
• A master clinical supply agreement with Roche secures atezolizumab for the Phase 3 trial.
• The company has successfully raised additional capital through its ATM program.

Negatives

• The company has incurred significant operating losses since inception.
• The company's net loss for the nine months ended September 30, 2024, was $28.03 million.
• The company has an accumulated deficit of $193.3 million as of September 30, 2024.
• The company is dependent on raising additional capital to continue operations.
• The company's loan agreement with Oxford Finance LLC has a floating interest rate and requires monthly principal payments.

Risks

• The company has a history of operating losses and may not achieve or sustain profitability.
• The company will need to raise additional funding to finance its operations, which may not be available on acceptable terms or at all.
• The terms of the Loan Agreement with Oxford Finance provide Oxford with a lien against all of the company's assets, including its intellectual property.
• The company's product candidates may not receive regulatory approval or achieve commercial success.
• The company faces significant competition in the biopharmaceutical industry.
• The company may rely on third parties to manufacture its clinical product supplies.
• The trading price of the company's common stock is likely to continue to be volatile.
• Unstable market and economic conditions may have serious adverse consequences on the company's business, financial condition and share price.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for at least the next several years as it continues the clinical development of its product candidates. The company believes its existing cash and cash equivalents will be sufficient to fund its cash requirements for at least 12 months following the issuance of these financial statements. The company intends to raise additional capital through the issuance of additional debt or equity, including in connection with potential merger opportunities, or through business development activities.

Management Comments

• Management believes that its existing cash and cash equivalents will be sufficient to fund the Companys cash requirements for at least 12 months following the issuance of these financial statements.
• Management plans to secure sources of financing and ultimately attain profitable operations.

Industry Context

The document highlights Tempest's progress in the competitive immuno-oncology space, particularly with its lead program amezalpat, which is moving towards a pivotal Phase 3 trial. The company is also exploring new indications for its other product candidates, reflecting a broader trend in the industry to diversify pipelines and target specific patient populations. The company's focus on novel mechanisms of action, such as PPAR and prostaglandin antagonism, positions it to potentially address unmet needs in cancer treatment.

Comparison to Industry Standards

• The reported median overall survival (OS) of 21 months for amezalpat in combination with atezolizumab and bevacizumab compares favorably to the standard of care, which typically shows an OS of around 15 months in first-line HCC.
• The objective response rate (ORR) of 30% for amezalpat is also competitive with other combination therapies in this space.
• Companies like Exelixis (Cabometyx) and Bayer (Nexavar) have established treatments for HCC, but Tempest's amezalpat is showing promising results in combination with the current standard of care.
• The development of TPST-1495 for FAP is a novel approach, as there are currently no approved systemic therapies for this condition, setting Tempest apart from other companies focused on more common cancer types.
• The company's reliance on third-party manufacturers is common in the biotech industry, but the risks associated with this reliance are significant and need to be managed carefully.
• The company's cash burn rate and need for additional funding are typical for a clinical-stage biotech company, but the ability to secure funding on favorable terms is crucial for continued development.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to market conditions and company-specific news.
• Employees may benefit from the company's growth and development of new therapies.
• Patients may benefit from the development of new cancer treatments.
• Creditors may be impacted by the company's financial performance and ability to repay debt.
• Suppliers may benefit from the company's increased demand for materials and services.

Next Steps

• Advance amezalpat into a pivotal study in first-line HCC patients.
• Explore TPST-1495 beyond original tumor types of interest, including completing the ongoing combination arm in patients with advanced endometrial cancer.
• Advance TPST-1495 with the Cancer Prevention Clinical Trials Network into a Phase 2 study in patients with FAP in the second half of 2024.

Key Dates

Keywords

amezalpat, TPST-1495, liver cancer, hepatocellular carcinoma, clinical trial, Phase 3, FDA, biotechnology, oncology, cancer treatment, PPAR antagonist, prostaglandin antagonist, Familial Adenomatous Polyposis, ATM program, Roche, atezolizumab